MARATTO

article · ALEXMED ePosters

EVALUATION OF KELL ANTIGEN PHENOTYPING VERSUS GENOTYPING IN EGYPTIAN MULTITRANSFUSED THALASSEMIC PATIENTS.

Abstract

Thalassemia is the most common hereditary single-gene disorder.Thalassemia patients typically require repeated RBC transfusions as their primary treatment option.The most common complication of RBC transfusion is alloimmunization against RBC antigens. The Kell blood group system is the third most significant immunogenic blood group system.Most studies have reported a high prevalence of antibodies against Kell system antigens in thalassemia patients. Accurate phenotyping of RBCs from transfused patients with thalassemia is a very complex process due to the presence of transfused donors RBCs in the recipient’s circulation. Molecular assays are not influenced by the presence of immunoglobulins or transfused cells and can be used to determine RBC antigens even in recently transfused patients or those receiving multiple blood transfusions. Therefore, using molecular blood group genotyping can support transfusion decisions and prevent alloimmunization by an antigen-matched transfusion in these patients.Aim:The aim of this study is to estimate Kell antigen among Egyptian multitransfused thalassemic pateints and evaluate the usefulness of kell antigen genotyping in addition to conventional serological phenotyping in order to determine the pateints who will benefit from this technique.

Research topics

  • Hemoglobinopathies and Related Disorders
  • Blood groups and transfusion
  • Liver Disease Diagnosis and Treatment

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/alexpo.2025.371767.2122

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.